CJC-1295 (No DAC) + Ipamorelin (Blend)
GHRH Analog + Ghrelin Mimetic Blend | Growth Hormone Pathway Research
Trusted by 65+ research professionals, labs, and institutions nationwide
Third-party Tested
COA Verified
Cold Storage
Same-day DeliveryFor research use only. Analytical reference material for in vitro work by qualified researchers. Learn more
Active Batch
CJI-202602-J1
Purity
Tested
Third-party TestedCOA VerifiedCold StorageSame-day DeliveryCJC-1295 (No DAC) + Ipamorelin Blend is a synergistic combination of two synthetic peptides: CJC-1295 without Drug Affinity Complex, a growth hormone-releasing hormone (GHRH) analog, and Ipamorelin, a selective growth hormone secretagogue receptor (GHS-R) agonist. With a combined molecular weight of approximately 3647.2 g/mol and CAS reference 446262-90-4, this blend has been studied in preclinical research for its complementary mechanisms of action—GHRH receptor activation paired with ghrelin-mimetic signaling—and their combined effects on pulsatile growth hormone release patterns in assay systems. Published literature has examined the pharmacological rationale for combining GHRH analogs with GHS-R agonists, including receptor cross-talk, somatostatin feedback modulation, and IGF-1 pathway signaling in cell-based and animal models. This blend is provided exclusively as a lyophilized research reagent for neuroendocrine pathway investigation. It is not intended for human or veterinary use, and no claims regarding growth hormone modulation or therapeutic efficacy are made or implied.
CJC-1295 (No DAC) + Ipamorelin Blend is a synergistic combination of two synthetic peptides: CJC-1295 without Drug Affinity Complex, a growth hormone-releasing hormone (GHRH) analog, and Ipamorelin, a selective growth hormone secretagogue receptor (GHS-R) agonist. With a combined molecular weight of approximately 3647.2 g/mol and CAS reference 446262-90-4, this blend has been studied in preclinical research for its complementary mechanisms of action—GHRH receptor activation paired with ghrelin-mimetic signaling—and their combined effects on pulsatile growth hormone release patterns in assay systems. Published literature has examined the pharmacological rationale for combining GHRH analogs with GHS-R agonists, including receptor cross-talk, somatostatin feedback modulation, and IGF-1 pathway signaling in cell-based and animal models. This blend is provided exclusively as a lyophilized research reagent for neuroendocrine pathway investigation. It is not intended for human or veterinary use, and no claims regarding growth hormone modulation or therapeutic efficacy are made or implied.
For Research Purposes Only
By purchasing this product, you acknowledge that you are a qualified researcher. Not for human or animal consumption.
Learn MoreCJC-1295 (No DAC) + Ipamorelin (Blend)
2 PubChem component profiles
%20+%20IPAMORELIN%20BLEND%2010MG.webp)
Active PubChem Profile
CJC-1295
CID 91971820
Known Synonyms
Identifiers
Molecular Formula
C165H269N47O46
InChIKey
ZUQGTWKGESAQCD-ZGFIGYLBSA-N
InChI
Computed Properties
CJC-1295 (No DAC) + Ipamorelin (Blend)
2 PubChem component profiles
Active PubChem Profile
CJC-1295
PubChem CID: 91971820
Known Synonyms
Identifiers
Computed Properties
CJC-1295 (No DAC) + Ipamorelin (Blend) — Research Reference
A research blend pairing a short-acting GHRH analogue (CJC-1295 without DAC) with a selective ghrelin receptor agonist (ipamorelin).
What is CJC-1295 (No DAC) + Ipamorelin (Blend)?
This product is a research-use blend of two peptides commonly paired in growth hormone axis studies: CJC-1295 without DAC (a synthetic GHRH analogue without the Drug Affinity Complex extension) and Ipamorelin (a pentapeptide that selectively agonises the ghrelin/growth hormone secretagogue receptor). The two peptides engage complementary pathways to stimulate pituitary GH release in research models, and blending them provides analytical-reference convenience for laboratories whose assays examine both compounds in parallel.
Mechanism in research literature
CJC-1295 (no DAC) binds the GHRH receptor on anterior pituitary somatotrophs, mimicking endogenous GHRH stimulation. Ipamorelin binds the growth hormone secretagogue receptor (GHS-R), engaging a distinct mechanistic axis. The combination produces a synergistic effect on pulsatile GH release described across multiple published studies — engaging two independent triggers for somatotroph activation. Ipamorelin's selectivity for GHS-R without significant activity at related receptors (such as those engaged by older GHRPs) is one reason it is widely chosen as a research probe for the ghrelin axis.
Documented research applications
Documented research contexts include somatotroph cell-culture studies, pulsatile GH release profiling, IGF-1 axis assays, and combination peptide pharmacology research. The blend simplifies bench handling for protocols requiring fixed-ratio dosing of the two compounds.
Reconstitution
Reconstitute the blended vial with bacteriostatic water at the volume specified on the batch documentation. Direct the diluent against the side wall of the vial, swirl gently, and allow full dissolution before drawing.
Storage & stability
Store the lyophilised blend at 2–8 °C. Reconstituted solution should be refrigerated at 2–8 °C and used within 3–4 weeks per typical stability windows.
Frequently asked questions
All Noxa Labs products are supplied strictly as analytical reference materials for qualified in vitro research. They are not pharmaceutical products, food supplements, or substances for human or animal consumption.
Pair CJC-1295 (No DAC) + Ipamorelin (Blend) with these peptides
Verified compounds researchers commonly add to their workflow.
BAC Water
3 ml
Melanotan II
10 mg
PT-141
10 mg
BPC-157
10 mg
GHK-Cu
100 mg
NAD+
100 mg
BAC Water
3 ml
Melanotan II
10 mg
PT-141
10 mg
BPC-157
10 mg
